乐心医疗2026年董事会决议公告深度分析

投资者需重点关注的关键事项（2026年4月10日）

广东乐心医疗电子股份有限公司（证券代码：300562）于2026年4月8日召开第五届董事会第九次会议，审议并通过了一系列重大议案。此次公告涉及2025年度经营业绩、利润分配、资本运作、现金管理、外汇风险管理、薪酬制度及股东大会召开等，均对公司未来发展及股东利益具有重要影响。以下为投资者整理的详细内容：

一、2025年度经营与财务报告

• 董事会及总经理工作报告：董事会和管理层被评价为勤勉尽责，严格执行各项决议，2025年度经营管理层有效执行董事会决策，整体经营运作良好。
• 年度报告及财务决算：报告内容真实、准确、完整，不存在虚假、误导或重大遗漏。年度报告、财务决算均已通过审计委员会审议，并将提交年度股东会审议。
• 利润分配预案：拟以218,613,688股为基数，每10股派发现金红利1.30元（含税），合计现金股利28,419,779.44元。不送红股、不以资本公积转增股本，剩余未分配利润结转至下年度。分红方案若股本变动将调整分配总额。

二、资本运作与资产管理

• 资产减值准备及核销：对存在减值迹象的资产进行了全面清查和减值准备核销，严格遵循会计准则，体现谨慎原则，确保财务状况真实反映。此举有助于提升公司资产质量，减少潜在风险。
• 会计政策变更：根据财政部最新准则解释（企业会计准则解释第19号）调整相关会计政策，确保公司财务报告与国家政策保持一致。
• 注册资本变更：受限股与股票期权激励计划影响，公司注册资本由217,406,188元增至218,573,688元。部分限制性股票回购注销，反映公司股本动态调整。

三、资金管理与风险控制

• 对外担保与银行授信：预计2026年度对外担保额度不超过人民币6亿元，综合授信额度不超过15亿元，均为支持公司及子公司业务发展、融资能力提升。担保与授信均为公司与全资子公司之间，风险可控，不涉及控股股东或关联人担保。
• 闲置资金现金管理：拟使用不超过1.7亿元闲置募集资金及5.5亿元闲置自有资金购买安全性高、流动性好的现金管理产品，提升资金使用效率，增加收益。
• 外汇衍生品套期保值：公司及子公司拟使用自有资金开展外汇衍生品套期保值业务，最高合约价值不超过1亿美元，有效防范汇率波动风险，降低财务费用，保障出口业务稳定。

四、公司治理与薪酬制度

• 独立董事评估：独立董事年度独立性自查与专项意见，确认独立董事未担任除独立董事外任何职务，无利害关系，符合监管要求。
• 会计师事务所续聘：继续聘任立信会计师事务所为2026年度审计机构，保障审计工作的连续性与专业性。
• 薪酬管理制度修订及方案：修订董事、高级管理人员薪酬管理制度，确认2025年度及拟定2026年度薪酬方案。董事、高管薪酬方案将提交股东会审议，薪酬政策参考行业、地区水平，保障激励与约束机制。
• 年度股东大会召集：定于2026年4月30日在公司会议室召开2025年度股东会，现场与网络投票结合，确保股东参与权利。

五、对股东及股价的影响

• 分红政策：现金分红有助于增强股东回报，提升股价吸引力。
• 资本、资产管理与现金管理：积极现金管理及资产减值准备，提升财务稳健性，降低风险，对公司长期价值构成正面影响。
• 外汇风险管理：针对出口业务开展外汇衍生品套期保值，有效控制财务波动，防范业绩风险。
• 高额银行授信与担保：为未来业务扩展提供资金保障，彰显公司扩张意图及融资能力。
• 薪酬制度修订与激励计划：有利于吸引和留住核心人才，保障公司治理与发展。

投资者提示

上述议案多数尚需提交2025年度股东大会审议通过，部分议案（如利润分配、对外担保、注册资本变更、薪酬方案等）对公司经营、资本结构及股东回报具有直接影响，可能引发市场关注并影响公司股价。建议投资者密切关注后续公告及股东大会决议。

免责声明

本文章仅供信息参考，内容基于公司公告信息，不构成任何投资建议。投资者应根据自身情况理性决策，并关注公司后续正式公告。

English Version

Detailed Analysis of Lekin Medical’s 2026 Board Resolutions

Key Highlights for Investors (April 10, 2026)

Guangdong Lekin Medical Electronics Co., Ltd. (stock code: 300562) held its 9th meeting of the 5th Board of Directors on April 8, 2026. The board reviewed and approved a series of major resolutions impacting the company’s operations, capital management, dividend policy, cash and FX management, compensation system, and the upcoming shareholder meeting. These resolutions are significant for future development and shareholder interests. Detailed highlights are as follows:

1. 2025 Operating and Financial Performance

• Board & General Manager Reports: Management is praised for diligence and strict execution of resolutions. The company operated effectively in 2025 with sound management practices.
• Annual Report & Financials: The annual report and financial statements are deemed accurate and complete, with no false or misleading disclosures. Both passed audit committee review and will be submitted to the shareholder meeting.
• Dividend Proposal: Based on 218,613,688 shares, a cash dividend of RMB 1.30 (tax included) per 10 shares is proposed, totaling RMB 28,419,779.44. No bonus shares or capital reserve transfers; undistributed profits carried forward. The dividend amount will be adjusted if share capital changes before implementation.

2. Capital Operations & Asset Management

• Asset Impairment & Write-off: Comprehensive review and impairment of assets showing signs of loss, strictly following accounting standards. This strengthens asset quality and reduces risk.
• Accounting Policy Change: Adjustments made per the latest Ministry of Finance guidelines (Interpretation No. 19), ensuring compliance.
• Capital Change: Due to stock incentive plans, registered capital increased from RMB 217,406,188 to RMB 218,573,688. Some restricted shares were repurchased and cancelled.

3. Cash Management & Risk Control

• Guarantees & Bank Credit: 2026 external guarantee limit set at RMB 600 million, comprehensive credit limit at RMB 1.5 billion for the company and subsidiaries—supports business growth and financing. Guarantees are inter-company, risk is controllable, and not involving controlling shareholders/related parties.
• Idle Fund Management: Up to RMB 170 million of idle raised funds and RMB 550 million of own funds to be used for purchase of safe, liquid cash products to enhance yield.
• FX Derivatives for Hedging: Up to USD 10 million (or equivalent RMB) in FX derivatives for hedging, protecting against currency risks due to substantial export business, lowering financial expenses.

4. Governance & Compensation

• Independent Director Evaluation: Annual independence check confirms compliance with regulatory requirements and no conflicts of interest.
• Audit Firm Reappointment: Continued appointment of Lixin CPA for 2026 ensures audit continuity and professional standards.
• Compensation Policy: Revised director/executive compensation management system and confirmed 2025 payments & 2026 plan. Proposals reflect industry/regional levels and company reality, to be submitted to shareholders.
• Annual Shareholder Meeting: Scheduled for April 30, 2026, with both on-site and online voting, preserving shareholder rights.

Potential Impact on Shareholders & Share Price

• Dividend Policy: Cash dividends enhance shareholder returns and may boost share price attractiveness.
• Asset & Cash Management: Proactive asset impairment and cash management improve financial stability, lower risks, and may positively influence company value.
• FX Risk Management: FX hedging protects against earnings volatility, stabilizing future performance.
• Large Bank Credit & Guarantee: Supports business expansion, signaling growth and strong financing capability.
• Compensation & Incentive Plans: Helps retain top talent, ensuring governance and sustainable growth.

Investor Reminder

Most resolutions require approval at the 2025 annual shareholder meeting. Key items such as dividend policy, guarantees, capital changes, and compensation schemes directly impact company operations and shareholder returns, and may attract market attention or influence share price. Investors are advised to closely follow further company announcements and shareholder meeting outcomes.

Disclaimer

This article is for informational purposes only, based on company disclosures. It does not constitute investment advice. Please make rational investment decisions and pay attention to subsequent official announcements.

View 乐心医疗 Historical chart here